ZAGAMI, PAOLA
ZAGAMI, PAOLA
Dipartimento di Oncologia ed Emato-Oncologia
Cardiotoxicity of Agents Used in Patients With Breast Cancer
2024 P. Zagami, D. Trapani, E. Nicolò, C. Corti, C. Valenza, C. Criscitiello, G. Curigliano, L.A. Carey
Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents
2023 E. Nicolò, P. Tarantino, O. D'Ecclesiis, G. Antonarelli, L. Boscolo Bielo, A. Marra, S. Gandini, E. Crimini, F. Giugliano, P. Zagami, C. Corti, D. Trapani, S. Morganti, C. Criscitiello, M. Locatelli, C. Belli, A. Esposito, I. Minchella, M. Cristofanilli, S.M. Tolaney, G. Curigliano
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors
2023 E. Zattarin, D. Presti, L. Mariani, C. Sposetti, R. Leporati, A. Menichetti, C. Corti, C. Benvenuti, G. Fuca, R. Lobefaro, F. Ligorio, L. Provenzano, A. Vingiani, M. Del Vecchio, G. Griguolo, M. Sirico, O. Bernocchi, A. Marra, P. Zagami, E. Agostinetto, F. Jacobs, P. Di Mauro, A. Esposito, C.A. Giorgi, L. Lalli, L. Boldrini, P.P.B. Giacchetti, A.C. Schianca, V. Guarneri, R. Pedersini, A. Losurdo, A. Zambelli, D. Generali, C. Criscitiello, G. Curigliano, G. Pruneri, F. de Braud, M.V. Dieci, C. Vernieri
Evolution of biological features of invasive lobular breast cancer: Comparison between primary tumour and metastases
2023 P. Trillo, J. Sandoval, D. Trapani, E. Nicolò, P. Zagami, F. Giugliano, P. Tarantino, G. Vivanet, L. Ascione, A. Friedlaender, A. Esposito, C. Criscitiello, G. Curigliano
Metaplastic breast cancer: an all-round multidisciplinary consensus
2023 G. Corso, C. Criscitiello, L. Nicosia, F. Pesapane, E. Vicini, F. Magnoni, A. Sibilio, C. Zanzottera, A.M. De Scalzi, S. Mannucci, M. Marabelli, M. Calvello, I. Feroce, P. Zagami, F.M. Porta, A. Toesca, P. Tarantino, E. Nicolò, G. Mazzarol, C. La Vecchia, B. Bonanni, M.C. Leonardi, P. Veronesi, N. Fusco
The rare entity of gastrointestinal leiomyosarcomas: An Italian multicenter retrospective study in high‐volume referral centers
2023 P. Zagami, A. Comandone, M. Fiore, G. Giulio Baldi, G. Grignani, B. Vincenzi, A. Gronchi, G. Antonarelli, A. Boglione, E. Pennacchioli, G. Curigliano, F. Conforti, T.M. De Pas
HER2-positive breast cancer: cotargeting to overcome treatment resistance
2023 P. Zagami, L.B. Bielo, E. Nicolo, G. Curigliano
Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure
2023 G. Antonarelli, C. Corti, P. Tarantino, B.T. Salimbeni, P. Zagami, A. Marra, D. Trapani, S. Tolaney, J. Cortes, G. Curigliano
Management of Patients with Cardiac Toxicity: The Point of View of the Oncologist
2022 P. Zagami, S. Morganti, P. Tarantino, G. Curigliano
Triple negative breast cancer: Pitfalls and progress
2022 P. Zagami, L.A. Carey
Baseline tumor size as prognostic index in patients with cancer receiving experimental targeted agents
2022 P. Tarantino, O. D'Ecclesiis, E. Nicolò, G. Antonarelli, L. Boscolo Bielo, A. Marra, S. Gandini, E. Crimini, F. Giugliano, P. Zagami, C. Corti, D. Trapani, S. Morganti, C. Criscitiello, M.A. Locatelli, C. Belli, A. Esposito, I. Minchella, S.M. Tolaney, G. Curigliano
Evolution of low HER2 expression between early and advanced-stage breast cancer
2022 P. Tarantino, S. Gandini, E. Nicolo, P. Trillo, F. Giugliano, P. Zagami, G. Vivanet, F. Bellerba, D. Trapani, A. Marra, A. Esposito, C. Criscitiello, G. Viale, G. Curigliano
Tumor-infiltrating lymphocytes (TILs) in paired samples from patients with phenotypic switch from early luminal-like to metastatic triple-negative breast cancer
2022 S. Morganti, A. Marra, K. Venetis, E. Sajjadi, L. Ascione, C. Corti, P. Zagami, M. Ivanova, L. Zattoni, G. Curigliano, N. Fusco, C. Criscitiello
Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial
2022 F. Conforti, P.A. Zucali, L. Pala, C. Catania, V. Bagnardi, I. Sala, P. Della Vigna, M. Perrino, P. Zagami, C. Corti, S. Stucchi, M. Barberis, E. Guerini-Rocco, B. Di Venosa, F. De Vincenzo, N. Cordua, A. Santoro, G. Giaccone, T.M. De Pas
Refining risk stratification in HR-positive/HER2-negative early breast cancer: how to select patients for treatment escalation?
2022 S. Morganti, A. Marra, E. Crimini, P. D'Amico, P. Zagami, G. Curigliano
Characterization of low HER2 expressions in de-novo metastatic breast cancer
2021 P. Tarantino, E. Nicolo, P. Zagami, F. Giugliano, P. Aliaga, E. Crimini, C. Corti, J. Uliano, S. Morganti, L. Mazzarella, C. Criscitiello, A. Esposito, G. Curigliano
Seroconversion in patients with cancer and oncology health care workers infected by SARS-CoV-2
2021 A. Marra, D. Generali, P. Zagami, V. Cervoni, S. Gandini, S. Venturini, S. Morganti, R. Passerini, R. Orecchia, G. Curigliano
Systemic Treatment of Ductal Carcinoma In Situ of the Breast
2021 E. Crimini, C. Corti, M. Repetto, F. Giugliano, G. Antonarelli, P. Tarantino, P. Zagami, S. Morganti, E. Nicolo, J. Uliano, G. Curigliano
Fed or fasted state for oral therapies in breast cancer treatment? A comprehensive review of clinical practice recommendations
2021 E. Nicolò, D. Trapani, P.P.M. Berton Giachetti, P. Zagami, G. Curigliano
Clinical outcomes of patients with metastatic breast cancer enrolled in phase I clinical trials
2021 C. Criscitiello, A. Marra, S. Morganti, P. Zagami, S. Gandini, A. Esposito, G. Curigliano